oxidative stress
Overview
Oxidative stress is the disruption of cellular redox balance that follows when reactive oxygen species (ROS) production outpaces the antioxidant systems that dispose of them. The chemistry runs in a defined sequence: electron leak from the mitochondrion respiratory chain, and the deliberate activity of NADPH oxidases in phagocytes and signaling compartments, produce superoxide; Superoxide Dismutase (SOD) dismutates superoxide to hydrogen peroxide; and hydrogen peroxide is then either reduced to water by Catalase (CAT), glutathione peroxidases and peroxiredoxins, or, in the presence of ferrous iron, converted by Fenton chemistry into the hydroxyl radical, which reacts with the first molecule it meets and has no enzymatic defense. The tripeptide glutathione supplies the reducing equivalents for much of this disposal, regenerated at the expense of NADPH. At controlled levels the same species are signals rather than poisons, driving the phagocyte respiratory burst and the reversible oxidation of cysteine residues that switches enzymes and transcription factors on and off; oxidative stress is better understood as the loss of that control than as the mere presence of ROS.
When disposal is outrun, ROS damage the macromolecules they encounter. Membrane lipid peroxidation, read out biochemically as malondialdehyde (MDA), is the most widely measured consequence and the same reaction that Glutathione Peroxidase 4 (GPX4) restrains to prevent ferroptosis; proteins accumulate carbonyl adducts and oxidized cysteines, and DNA acquires lesions such as 8-oxo-guanine. Cells answer through the kelch like ECH associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (Nrf2) axis, in which oxidation of KEAP1 cysteines releases Nrf2 to transcribe the antioxidant and detoxification program, while nuclear factor kappa B (NF-κB) couples the same signals to inflammatory transcription. Sustained stress engages autophagy, apoptotic cascades and cellular senescence, each of which can in turn alter ROS production.
That reciprocity is what makes oxidative stress difficult to place causally: it drives pathology in neurodegeneration, cardiovascular disease, diabetic complications, cancer and aging, and is also generated by those same processes, so in most diseases it is both cause and consequence rather than either alone. The therapeutic history reflects this. Large trials of indiscriminate dietary antioxidants such as vitamin E and β-carotene produced no benefit and occasional harm, consistent with blunting redox signaling the cell requires, and attention has moved instead to targeted approaches — Nrf2 activators, mitochondria-directed antioxidants, and iron chelation — that aim at a specific source or compartment rather than at ROS in general.
Recent Publications Summary
Recent studies have examined oxidative stress across diverse disease contexts, most often as a mechanistic target linked to reactive oxygen species, mitochondrial dysfunction, inflammation, and tissue injury. In non-diabetic patients with metabolic dysfunction-associated steatotic liver disease, a randomized controlled trial found that 12 weeks of high-dose N-acetylcysteine plus lifestyle intervention did not significantly change serum malondialdehyde, insulin resistance markers, or FibroScan-based liver measures compared with lifestyle intervention alone 42587287Aug. In contrast, several preclinical studies used oxidative stress as a therapeutic entry point, including a photobiomodulation therapy protocol for chronic non-specific knee pain that proposed modulation of oxidative stress alongside inflammatory and functional outcomes 42552011Aug, and a heart-targeted nanomedicine designed to rapidly restore mitochondrial function after myocardial infarction by synergistically modulating mitochondrial membrane potential and oxidative stress 41696142Feb.
A number of experimental cancer and neurodegeneration studies focused on suppressing oxidative stress to alter disease progression. In pancreatic ductal adenocarcinoma cells, glycyrrhetinic acid and autocrine motility factor converged on G6PD suppression, sustained ROS accumulation, and impaired cell growth, with additional effects on drug retention 42527054Jul. In Alzheimer's disease models, an oxidative stress-responsive nanocomposite released donepezil and RuO2-TPP in response to elevated hydrogen peroxide, interrupted the oxidative stress cascade, repaired mitochondrial dysfunction, and activated mitophagy in APP/PS1 mice 42441421Jul. Another Alzheimer's-related study reported that Broussonetia papyrifera fruit extract attenuated pathogenesis by disrupting the reciprocal exacerbation between Aβ proteotoxicity and oxidative stress in C. elegans and cellular models 41819509Mar.
Oxidative stress was also investigated in metabolic, renal, ocular, and endocrine disease models. In type 1 diabetes, cerium-layered double hydroxide nanoparticles loaded with MCC950 were designed to inhibit NLRP3 inflammasome activation and oxidative stress; the formulation eliminated Intracellular ROS in MIN-6 cells and reduced apoptosis, with pancreas-targeted accumulation in streptozotocin-induced diabetic mice 42144245May. Nicotiflorin was reported to improve septic acute kidney injury by restoring mitochondrial function, reducing oxidative stress, and involving the PINK1/Parkin pathway 41730753Feb. A study in pseudoexfoliation syndrome assessed oxidative stress markers and thiol-disulfide homeostasis in relation to ocular and systemic comorbidities 42371156Jun, while Arthrospira platensis was reported to prevent impairment of intestinal smooth muscle relaxation in diet-induced obesity through modulation of nitric oxide, prostanoid, and oxidative stress pathways 41833761Mar.
Across these publications, oxidative stress frequently appeared as part of broader multimodal strategies rather than as an isolated endpoint. Reviews highlighted its relevance in integrative dermatology for skin aging and in bioactive natural products that modulate autophagy, where alleviation of oxidative stress was described alongside effects on inflammation and mitochondrial homeostasis 41926038Apr41830033Mar. Overall, the recent literature portrays oxidative stress as a recurring translational target in antioxidant supplementation, nanomedicine, natural products, and mitochondrial rescue approaches, with outcomes ranging from null effects in a clinical MASLD trial to promising preclinical benefits in cancer, neurodegeneration, diabetes, kidney injury, and myocardial infarction 42587287Aug42527054Jul42441421Jul42144245May41730753Feb41696142Feb.
What Changes, What Holds
1. Null clinical change with N-acetylcysteine leaves antioxidant supplementation unproven in MASLD
REINFORCES High-dose N-acetylcysteine added to lifestyle intervention did not move malondialdehyde, insulin resistance, or FibroScan measures in non-diabetic MASLD, which fits the Overview’s caution that broad antioxidant strategies often fail to deliver clinical benefit 42587287Aug. The main implication is not a new role for oxidative stress, but a reminder that lowering presumed redox burden does not reliably translate into measurable disease modification in humans.
2. Oxidative-stress targeting is being used as a therapeutic delivery strategy in cancer, neurodegeneration, and injury repair
NEW DIRECTION An oxidative-stress-responsive nanocomposite, heart-targeted nanomedicine, and G6PD-suppressing cancer approach all treat oxidative stress as a trigger or handle for targeted intervention rather than a generic damage marker 42441421Jul41696142Feb. This extends the Overview’s targeted-therapy theme, but the broader change is that redox imbalance is now being engineered into drug release, organ targeting, and pathway control; none of that displaces the baseline mechanism.
3. Mitochondrial rescue and inflammasome control remain compatible ways to restrain oxidative injury in metabolic and renal disease
REINFORCES Cerium-layered nanoparticles with MCC950, nicotiflorin in septic kidney injury, and other metabolic/ocular/intestinal studies all keep oxidative stress in the expected role of a downstream injury amplifier and treatment target 42144245May41730753Feb. The mixed human and animal signals do not challenge the settled account; instead they sharpen it by showing that disease-specific benefits depend on restoring mitochondrial function, limiting ROS, or damping inflammatory loops rather than on nonspecific antioxidant replacement.
4. Oxidative stress is increasingly treated as a co-driver of proteotoxic and aging-related pathology, not a standalone endpoint
REINFORCES Broussonetia fruit extract in Alzheimer-related models and reviews in skin aging and autophagy place oxidative stress alongside inflammation, mitochondrial homeostasis, and proteotoxic stress as part of broader disease circuits 41819509Mar41926038Apr41830033Mar. That is consistent with the Overview’s reciprocity between redox imbalance and pathology: the new work reinforces bidirectionality and multimodal intervention, but it does not require revising the core definition or chemistry of oxidative stress.
Overview update candidates: null clinical efficacy of NAC in MASLD; oxidative-stress-responsive and heart-targeted delivery strategies; mitochondrial rescue as a disease-modifying approach in preclinical injury models.
oxidative stress
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding oxidative stress are described as follows:
- reactive oxygen species (Chemical) — 22 papers: PMIDs 42587527, 42452855, 42421649, 42349732, etc.
- Alzheimer's disease (Disease) — 16 papers: PMIDs 42554796, 42550339, 42527927, 42496889, etc.
- inflammation (Biological Process) — 14 papers: PMIDs 42587527, 42579421, 42550246, 42507735, etc.
- mitochondrial dysfunction (Biological Process) — 14 papers: PMIDs 42484070, 42476966, 42471196, 42456907, etc.
- diabetic nephropathy (Disease) — 11 papers: PMIDs 42494251, 42485434, 42456907, 42367005, etc.
- cardiovascular disease (Disease) — 9 papers: PMIDs 42587527, 42566559, 42503780, 42332914, etc.
- Neuroinflammation (Biological Process) — 9 papers: PMIDs 42554796, 42541634, 42496889, 42496765, etc.
- overt diabetes (Disease) — 9 papers: PMIDs 42467274, 42446804, 42437006, 42430106, etc.
- acute kidney injury (Disease) — 7 papers: PMIDs 42435348, 42400592, 42368402, 42301266, etc.
- blood–brain barrier (Biological Process) — 7 papers: PMIDs 42481908, 42313933, 42173608, 42140391, etc.
- ferroptosis (Biological Process) — 7 papers: PMIDs 42471196, 42435348, 42431470, 42165632, etc.
- hyperglycemia (Biological Process) — 6 papers: PMIDs 42507735, 42479468, 42421649, 41990582, etc.
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study oxidative stress:
- Superoxide Dismutase (SOD) (Protein) — 16 papers: PMIDs 42554876, 42550246, 42485542, 42478584, etc.
- western blot (Technology) — 16 papers: PMIDs 42593631, 42527054, 42501172, 42496889, etc.
- Rat (Organism) — 15 papers: PMIDs 42560997, 42550339, 42550246, 42541634, etc.
- reactive oxygen species (Chemical) — 14 papers: PMIDs 42550339, 42489635, 42478957, 42474786, etc.
- mouse (Organism) — 13 papers: PMIDs 42570757, 42503530, 42485438, 42455768, etc.
- high-fat diet (Other) — 11 papers: PMIDs 42507735, 42467274, 42446786, 42442304, etc.
- hydrogen peroxide (Chemical) — 11 papers: PMIDs 42581011, 42531223, 42474786, 42455178, etc.
- mice (Organism) — 11 papers: PMIDs 42507735, 42494251, 42485542, 42411797, etc.
- molecular docking (Technology) — 10 papers: PMIDs 42587240, 42496889, 42492702, 42470003, etc.
- Network Pharmacology (Technology) — 10 papers: PMIDs 42492702, 42470003, 42313000, 42066826, etc.
- Wistar Rat (Organism) — 10 papers: PMIDs 42554876, 42496765, 42478942, 42430839, etc.
- glutathione (Chemical) — 9 papers: PMIDs 42570757, 42485542, 42478957, 42474786, etc.
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to oxidative stress include:
- heme oxygenase 1 (Gene) — 6 papers: PMIDs 42478942, 42467274, 42202464, 42134761, etc.
- Nuclear factor erythroid 2-related factor 2 (NRF2) (Protein) — 6 papers: PMIDs 42478942, 42412905, 42134761, 42105997, etc.
- reactive oxygen species (Chemical) — 6 papers: PMIDs 42479468, 42412905, 42144245, 41989817, etc.
- resveratrol (Chemical) — 6 papers: PMIDs 42440180, 42431470, 42159899, 42061133, etc.
- Nrf-2-SLC7A11-GSH pathway (Pathway) — 5 papers: PMIDs 42381381, 42217658, 42202464, 42177922, etc.
- quercetin (Chemical) — 5 papers: PMIDs 42485438, 42061133, 42025668, 41732673, etc.
- celastrol (Therapy) — 4 papers: PMIDs 42525168, 42440432, 42301266, 42177922
- curcumin (Chemical) — 4 papers: PMIDs 42586992, 42061133, 42033875, 41875680
- doxorubicin (Therapy) — 4 papers: PMIDs 42120770, 42081994, 42070610, 41855820
- NLRP3 inflammasome (Protein) — 4 papers: PMIDs 42410254, 42202464, 42154340, 42144245
- proinflammatory cytokine (Biological Process) — 4 papers: PMIDs 42406869, 42333921, 42272250, 42154340
- SIRT6/NRF2/GPX4 signaling pathway (Pathway) — 4 papers: PMIDs 42467274, 42214028, 42114775, 41992617
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with oxidative stress include:
- reactive oxygen species (Chemical) — 49 papers: PMIDs 42581011, 42547693, 42541634, 42527054, etc.
- apoptotic process (Biological Process) — 33 papers: PMIDs 42495771, 42478957, 42478942, 42470003, etc.
- proinflammatory cytokine (Biological Process) — 33 papers: PMIDs 42525168, 42485542, 42478942, 42461351, etc.
- Superoxide Dismutase (SOD) (Protein) — 22 papers: PMIDs 42587240, 42581011, 42550339, 42533017, etc.
- lipid peroxidation (Biological Process) — 21 papers: PMIDs 42593674, 42587240, 42579653, 42533017, etc.
- malondialdehyde (Biological Process) — 19 papers: PMIDs 42587240, 42581011, 42579653, 42560997, etc.
- progression-free survival (Clinical Metric) — 17 papers: PMIDs 42425715, 42420599, 42415230, 42413328, etc.
- inflammation (Biological Process) — 16 papers: PMIDs 42586992, 42566559, 42497259, 42495771, etc.
- Caspase-3 (CASP3) (Protein) — 15 papers: PMIDs 42521892, 42501148, 42496765, 42485542, etc.
- glutathione (Chemical) — 15 papers: PMIDs 42587240, 42570757, 42547693, 42527927, etc.
- Catalase (CAT) (Protein) — 13 papers: PMIDs 42587240, 42579653, 42554758, 42550339, etc.
- inflammatory response (Biological Process) — 13 papers: PMIDs 42470003, 42466700, 42456907, 42446786, etc.
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding oxidative stress are summarized below:
- inflammation (Biological Process) — 12 papers: PMIDs 42587527, 42560997, 42554758, 42521892, etc.
- therapeutic target (Other) — 6 papers: PMIDs 42527927, 42412755, 42393179, 42371227, etc.
- neuroprotection (Biological Process) — 5 papers: PMIDs 42496765, 42484748, 42481908, 42467274, etc.
- neuroprotective effects (Clinical Metric) — 5 papers: PMIDs 42584743, 42436556, 42050372, 41910542, etc.
- Redox Balance (Biological Process) — 5 papers: PMIDs 42276496, 42159899, 41961470, 41922124, etc.
- apoptotic process (Biological Process) — 4 papers: PMIDs 42521892, 42485542, 41921766, 41831692
- cancer immunotherapy (Biological Process) — 4 papers: PMIDs 42170851, 41952381, 41941350, 41872688
- ferroptosis (Biological Process) — 4 papers: PMIDs 42461458, 42435348, 42002905, 41952381
- therapeutic potential (Other) — 4 papers: PMIDs 42202638, 42160747, 42154340, 42095973
- Therapy (Therapy) — 4 papers: PMIDs 42527054, 42349733, 42172897, 41918200
- Alzheimer's disease (Disease) — 3 papers: PMIDs 42554796, 42550339, 42441421
- Cardiovascular disorders (Disease) — 3 papers: PMIDs 42531223, 42206476, 42085490